



Nanotechnologies for the Life Sciences

Edited by Challa Kumar

 WILEY-VCH

Nanomaterials for Cancer Diagnosis



Contents

Preface *XVII*

List of Authors *XXI*

1	Dendrimers in Cancer Treatment and Diagnosis	1
	<i>Srinivasa-Gopalan Sampathkumar, and Kevin J. Yarema</i>	
1.1	Overview	1
1.2	Introduction	1
1.3	Basic Properties and Applications of Dendrimers	3
1.3.1	Structural Features and Chemical and Biological Properties	3
1.3.1.1	Basic Features of Dendritic Macromolecules are Inspired by Nature	3
1.3.1.2	Comparison of the Properties of Dendrimers and Conventional Synthetic Polymers	5
1.3.1.3	Comparison of the Properties of Dendrimers and Proteins (a Biological Polymer)	6
1.3.2	Dendritic Macromolecules Possess a Wealth of Possible Applications	8
1.4	Methods for Dendrimer Synthesis	10
1.4.1	History and Basic Strategies	10
1.4.1.1	Cascade Reactions are the Foundation of Dendrimer Synthesis	10
1.4.1.2	Dendrimer Synthesis has Expanded Dramatically in the Past Two Decades	12
1.4.2	Strategies, Cores, and Building Blocks for Dendritic Macromolecules	12
1.4.2.1	Dendrimers are Constructed from Simple “Building Blocks”	12
1.4.2.2	The Synthesis of Dendrimers Follows Either a Divergent or Convergent Approach	13
1.4.3	Heterogeneously-functionalized Dendrimers	13
1.4.3.1	Basic Description and Synthetic Considerations	13
1.4.3.2	Glycosylation is an Example of Surface Modification with Multiple Bioactivities	14
1.5	Dendrimers in Drug Delivery	15
1.5.1	Dendrimers are Versatile Nano-devices for the Delivery of Diverse Classes of Drugs	15

1.5.2	Dendritic Drug Delivery: Encapsulation of Guest Molecules	16
1.5.2.1	Dendrimers have Internal Cavities that can Host Encapsulated Guest Molecules	16
1.5.2.2	Using Dendrimers for Gene Delivery	16
1.5.2.3	Release of Encapsulated “Pro-drugs”	17
1.5.3	Covalent Conjugation Strategies	17
1.5.3.1	Dendrimers Overcome many Limitations Inherent in Polymeric Conjugation Strategies	17
1.5.3.2	Dendrimer Conjugates can be Used as Vaccines	19
1.5.3.3	Release of Covalently-delivered “Pro-drugs”	19
1.5.4	Fine-tuning Dendrimer Properties to Facilitate Delivery and Ensure Bioactivity	20
1.5.4.1	Delivery Requires Avoiding Non-specific Uptake	20
1.5.4.2	“Local” Considerations: Contact with, and Uptake by, the Target Cell	21
1.5.5	Drug Delivery: Ensuring the Biocompatibility of Dendritic Delivery Vehicles	22
1.5.5.1	Biocompatibility Entails Avoiding “Side Effects” such as Toxicity and Immunogenicity	22
1.5.5.2	Water Solubility and Immunogenicity	22
1.5.5.3	Inherent and Induced Toxicity	23
1.6	Dendrimers in Cancer Diagnosis and Treatment	24
1.6.1	Dendrimers have Attractive Properties for Cancer Treatment	24
1.6.2	Dendrimer-sized Particles Passively Accumulate at the Sites of Tumors	24
1.6.3	Multifunctional Dendrimers can Selectively Target Biomarkers found on Cancer Cells	25
1.6.3.1	Methods for Targeting Specific Biomarkers of Cancer	25
1.6.3.2	Targeting by Folate, a Small Molecule Ligand	26
1.6.3.3	Targeting by Monoclonal Antibodies	26
1.6.4	Dendrimers in Cancer Diagnosis and Imaging	28
1.6.4.1	Labeled Dendrimers are Important Research Tools for Biodistribution Studies	28
1.6.4.2	Towards Clinical Use: MRI Imaging Agents	28
1.6.5	Steps Towards the Clinical Realization of Dendrimer-based Cancer Therapies	29
1.6.5.1	The Stage is now set for Dendrimer-based Cancer Therapy	29
1.6.5.2	Boron Neutron Capture Therapy	29
1.6.6	Innovations Promise to Speed Progress	30
1.6.6.1	“Mix-and-Match” Strategy of Bifunctional Dendritic Clusters	30
1.6.6.2	Towards Therapeutic Exploitation of Glycosylation Abnormalities found in Cancer	31
1.6.6.3	Towards Targeting Metabolically-engineered Carbohydrate Epitopes	31
1.7	Concluding Remarks	33

Acknowledgments 33

References 33

2 Nanoparticles for Optical Imaging of Cancer 44

Swadeshmukul Santra and Debamitra Dutta

- 2.1 Introduction 44
- 2.2 Cancer Imaging Techniques 46
 - 2.2.1 Computed Tomography (CT) Scanning 47
 - 2.2.2 Magnetic Resonance (MR) 47
 - 2.2.3 Positron Emission Tomography (PET) 47
 - 2.2.4 Single-photon Emission CT (SPECT) 48
 - 2.2.5 Ultrasonography (US) 48
- 2.3 Optical Imaging 48
 - 2.3.1 Basics of Optical Imaging 48
 - 2.3.2 Optical Imaging Techniques 49
 - 2.3.3 Optical Contrast Agents 50
- 2.4 Nanoparticles for Optical Imaging 51
 - 2.4.1 Why Nanoparticles for Optical Imaging? 51
 - 2.4.2 Development of Nanoparticle-based Contrast Agents 53
 - 2.4.2.1 Quantum Dots 53
 - 2.4.2.2 Gold Nanoparticles 57
 - 2.4.2.3 Dye-doped Silica Nanoparticles 61
- 2.5 Optical Imaging of Cancer with Nanoparticles 65
 - 2.5.1 Active Targeting 65
 - 2.5.2 Passive Targeting 66
 - 2.5.3 Cancer Imaging with Quantum Dots 66
 - 2.5.4 Cancer Imaging with Gold Nanoparticles 68
 - 2.5.5 Cancer Imaging with Dye-doped Silica Nanoparticles 69
- 2.6 Other Nanoparticle-based Optical Contrast Agents 70
- 2.7 Conclusions and Perspectives 70
- Acknowledgments 72
- References 72

3 Nanogold in Cancer Therapy and Diagnosis 86

Priyabrata Mukherjee, Resham Bhattacharya, Chitta Ranjan Patra, and Debabrata Mukhopadhyay

- 3.1 Introduction 86
- 3.2 Medicinal use of Gold: A Historical Perspective 87
- 3.3 Application of Gold Nanoparticles in Cancer 88
 - 3.3.1 Angiogenesis and Cancer 88
 - 3.3.1.1 Agents that Inhibit Endothelial Proliferation or Response 90
 - 3.3.1.2 Agents that Block Activation of Angiogenesis 91
 - 3.3.1.3 Agents that Block Extracellular Matrix Breakdown 91
 - 3.3.1.4 Unique Anti-angiogenic Properties of Gold Nanoparticles 91

3.3.1.5	Gold Nanoparticles Inactivate VEGF165	92
3.3.1.6	What is the Mechanism of Action?	93
3.3.1.7	Effect of Gold Nanoparticles on the Activity of VEGF165, VEGF121, bFGF and EGF	94
3.3.1.8	Effect of Gold Nanoparticles on Signaling Events of VEGF165	94
3.3.1.9	Effect of Nanogold on Downstream Signaling events of VEGF165	95
3.3.1.10	Effect of Gold Nanoparticles on Migration of HUVEC Cells	95
3.3.1.11	Effect of Gold Nanoparticles on Angiogenesis <i>in vivo</i>	95
3.3.1.12	Gold Radioisotopes in Cancer Treatment	96
3.3.2	Application of Gold Conjugates in the Treatment of Cancer	96
3.3.2.1	Gold-TNF Conjugate in Cancer Therapeutics	96
3.3.2.2	"2 in 1" System in Cancer Therapeutics	97
3.4	Biocompatibility of Gold Nanoparticles	99
3.4.1	Cellular Adhesion Effects	99
3.4.2	Local Biological Effects	99
3.4.3	Systemic and Remote Effects	99
3.4.4	Effects of the Host on the Implant	100
3.4.5	Addressing the Biocompatibility of Gold Nanoparticles using DNA Microarray Analysis	100
3.4.6	Internalization of Gold Nanoparticles by HUVECs	101
3.4.7	Nanogold Particles do not Alter Global Pattern of Transcription by HUVEC Cells under Serum-free Conditions	101
3.4.8	Nanogold Particles do not Alter the Global Pattern of Transcription by HUVECs in Near-normal Culture Conditions	103
3.5	Synthetic Approaches to Gold Nanoparticles	105
3.5.1	Chemical Methods	105
3.5.2	Physical Methods	105
3.5.3	Biological Methods	106
3.6	Nanotechnology in Detection and Diagnosis with Gold Nanoparticles	106
3.6.1	Cancer Detection	106
3.6.2	Detection in DNA	107
3.6.2.1	Single-mismatch Detection in DNA	107
3.7	Future Direction	109
	Acknowledgments	110
	References	110
4	Nanoparticles for Magnetic Resonance Imaging of Tumors	121
	<i>Tillmann Cyrus, Shelton D. Caruthers, Samuel A. Wickline, and Gregory M. Lanza</i>	
4.1	Introduction	121
4.2	Magnetic Resonance Imaging (MRI)	121
4.3	Targeting Mechanisms	124
4.3.1	Passive versus Active Targeting	124
4.4	Superparamagnetic Nanoparticles	126
4.4.1	Ligand-directed Targeting of Iron Oxides	127

4.4.2	Cell Tracking of Iron Oxides	128
4.5	Paramagnetic Nanoparticles	128
4.5.1	Perfluorocarbon Nanoparticles	129
4.5.2	Liposomes	131
4.5.3	Fullerenes	132
4.5.4	Nanotubes	133
4.5.5	Dendrimers	133
4.6	Quantum Dots	133
4.7	Polymer Nanoparticles	134
4.8	Conclusion	135
	References	138
5	Magnetic Resonance Nanoparticle Probes for Cancer Imaging	147
	<i>Young-wook Jun, Jung-tak Jang, and Jinwoo Cheon</i>	
5.1	Introduction	147
5.2	Magnetic Nanoparticle Contrast Agents	150
5.2.1	Silica- or Dextran-coated Iron Oxide Contrast Agents	150
5.2.2	Magnetoferritin	152
5.2.3	Magnetodendrimers and Magnetoliposomes	152
5.2.4	New Type of Contrast Agent: Non-hydrolytically Synthesized High Quality Iron Oxide Nanoparticles	154
5.3	Iron Oxide Nanoparticles in Molecular MR Imaging	157
5.3.1	Infarct and Inflammation	158
5.3.2	Angiogenesis	159
5.3.3	Apoptosis	160
5.3.4	Gene Expression	161
5.3.5	Cancer Imaging	163
5.4	Summary and Outlook	166
	References	169
6	LHRH Conjugated Magnetic Nanoparticles for Diagnosis and Treatment of Cancers	174
	<i>Carola Leuschner</i>	
6.1	Introduction	174
6.2	Cancer	175
6.2.1	Conventional Approaches to Cancer/Metastases Detection	177
6.2.2	Current Chemotherapeutic Approaches and their Disadvantages in Cancer Treatments	179
6.2.2.1	Multidrug Resistance	179
6.2.2.2	Drug Delivery to Tumors	180
6.3	Nanoparticles as Vehicles for Drug Delivery and Diagnosis	181
6.3.1	Targeting Tumor Cells	183
6.3.1.1	Passive Targeting	183
6.3.1.2	Active Targeting	185
6.3.2	Detection of Tumors and Metastases using Nanoparticles	186

6.3.2.1	Nanoparticles for Magnetic Resonance Imaging	186
6.3.2.2	Targeted Delivery of Nanoparticles to Increase Cellular Uptake for Higher MRI Resolution	188
6.4	LHRH and its Receptors	189
6.4.1	The Ligand Luteinizing Hormone Releasing Hormone – LHRH	189
6.4.2	Analogues of LHRH	192
6.4.3	Receptors for LHRH	193
6.4.4	Function–Signal Transduction Pathways	194
6.4.5	LHRH Receptor-mediated Uptake	197
6.4.6	LHRH Receptor Type II	198
6.5	LHRH-bound Magnetic Nanoparticles	201
6.5.1	Synthesis and Characterization	201
6.5.2	Treatment using Hyperthermia	202
6.5.3	Treatment using Lytic Peptides	203
6.5.3.1	Destruction of Metastases through LHRH-SPION-Hecate	203
6.5.4	Detection of Tumors and Metastases	204
6.5.4.1	Targeted Delivery of SPION Contrast Agents for MRI	204
6.5.4.2	<i>In Vitro</i> Studies on Receptor-targeted LHRH-SPION Uptake	205
6.5.4.3	<i>In Vivo</i> Studies on Receptor-targeted LHRH-SPION Uptake	206
6.6	Future Outlook	210
	Acknowledgments	212
	Abbreviations	212
	References	213
7	Carbon Nanotubes in Cancer Therapy and Diagnosis	232
	<i>Pu Chun Ke and Lyndon L. Larcom</i>	
7.1	Overview	232
7.2	SWNT Modification for Solubility and Biocompatibility	234
7.2.1	Chemical Modifications of SWNTs for Solubility	234
7.2.1.1	Functionalization of SWNTs through Oxidation	235
7.2.1.2	Functionalization of SWNTs through Covalent Modifications	236
7.2.2	Noncovalent Modifications of SWNTs for Solubility	237
7.2.2.1	Solubilization of SWNTs Using Lysophospholipids Enables Cellular Studies	239
7.3	Diffusion of SWNT–Biomolecular Complexes	247
7.4	Gene and Drug Delivery with SWNT Transporters	252
7.4.1	RNA Translocation with SWNT Transporters	253
7.4.2	Gene Transfection with SWNT Transporters	258
7.4.3	Gene Transfection with SWNT Transporters for RNA Interference	261
7.4.4	Drug Delivery with SWNT Transporters	263
7.4.4.1	Vaccine Delivery by SWNTs	263
7.4.4.2	Protein Delivery by SWNTs	266
7.4.4.3	Biosensing by SWNTs	269
7.5	Sensing and Treating Cancer Cells Utilizing SWNTs	269
7.6	Cytotoxicity of SWNTs	272

7.7	Cancers and SWNTs	275
7.8	Summary	277
	Acknowledgments	278
	References	278
8	Nanotubes, Nanowires, Nanocantilevers and Nanorods in Cancer Treatment and Diagnosis	285
	<i>Kiyotaka Shiba</i>	
8.1	Introduction	285
8.2	Nanotubes, Nanowires and Nanorods	285
8.2.1	Carbon Nanotubes	286
8.2.2	Noncarbon Nanotubes	287
8.2.3	Single-wall Carbon Nanohorns	287
8.2.4	Nanorods and Nanowires	288
8.2.5	Self-assembled Nanotubes	289
8.3	Cancer Diagnosis	290
8.3.1	Carbon Nanotube-based Detection System	290
8.3.2	Non-carbon Nanotube-based Detection Systems	291
8.3.3	Microcantilevers	292
8.3.4	Nano-tag made of Nanorods	293
8.4	Cancer Treatment	293
8.4.1	Carriers for Drug Delivery Systems	294
8.4.2	Imaging Agents	294
8.5	Conclusions	295
	References	296
9	Multifunctional Nanotubes and Nanowires for Cancer Diagnosis and Therapy	304
	<i>Sang Bok Lee and Sang Jun Son</i>	
9.1	Introduction	304
9.2	Advanced Technologies in Magnetic Nanoparticles for Biomedical Applications	305
9.2.1	MRI and Therapeutic Application of Magnetic Nanoparticles	305
9.2.2	Biomedical Diagnostic Application of Magnetic Nanoparticles	307
9.3	Carbon Nanotubes	310
9.3.1	Carbon Nanotubes for Targeted Cancer Cell Death	310
9.3.2	Carbon Nanotubes for Detection of Cancer Cell	312
9.3.3	Carbon Nanotubes for Targeted Delivery	313
9.4	Nanotubes and Nanowires Composed of Artificial Peptides	315
9.4.1	Peptide Nanotubes	315
9.4.2	Peptide-Amphiphile Nanofibers	316
9.5	Template-synthesized Nanotubes and Nanorods	318
9.5.1	Differential Functionalization of Nanotube	319
9.5.2	Selective Extraction of Drug Molecules	320
9.5.3	Silica Nanotube Carrier for DNA Transfection	322

9.5.4	DNA Nanotubes	323
9.5.5	Nanobarcodes for Multiplexing Diagnosis	325
9.5.6	Magnetic Nanotubes	328
9.5.6.1	Synthesis and Characterization of Magnetic Nanotubes	328
9.5.6.2	Magnetic Field-assisted Chemical Separation and Biointeraction	329
9.5.6.3	Drug Uptake and Controlled Release	330
9.6	Conclusion	332
	References	333

10 Nanoprobe-based Affinity Mass Spectrometry for Cancer Marker Protein Profiling 338

Li-Shing Huang, Yuh-Yih Chien, Shu-Hua Chen, Po-Chiao Lin, Kai-Yi Wang, Po-Hung Chou, Chun-Cheng Lin, and Yu-Ju Chen

10.1	Introduction	338
10.2	Fabrication and Biomedical Applications of Nanoparticles	339
10.2.1	Fabrications and Properties of Nanoparticles	339
10.2.2	Metal Nanoparticles in Cancer Diagnosis	343
10.3	Principles of Mass Spectrometry	348
10.3.1	Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry	348
10.3.2	Affinity Mass Spectrometry	349
10.4	Nanoprobe-based Affinity Mass Spectrometry (NBAMS)	350
10.4.1	Preparation of Nanoprobe and Workflow	351
10.4.2	Proof-of-principle Experiment	353
10.4.3	Kinetic Study of the Nanoscale Immunoreaction	356
10.4.4	Detection Limit and Concentration Effect of Nanoprobe-based Immunoassay	356
10.5	Human Plasma and Whole Blood Analysis by Nanoprobe-based Affinity Mass Spectrometry	359
10.5.1	Selected Protein Profiling from Human Plasma	359
10.5.2	Comparison of Nanoscale and Microscale Immunoassay	359
10.5.3	Suppression of Nonspecific Binding on Magnetic Nanoparticles	361
10.5.4	Enrichment of Target Antigen in Human Plasma	362
10.5.5	Plasma Protein Profiling in Normal Individuals and in Patients	364
10.6	Multiplex Assay	364
10.6.1	Workflow of Multiplexed Assay	366
10.6.2	Screening for Patient and Healthy Individuals	367
10.7	Future Outlook	369
	Acknowledgments	369
	References	369

11	Nanotechnological Approaches to Cancer Diagnosis: Imaging and Quantification of Pericellular Proteolytic Activity	377
	<i>Thomas Ludwig</i>	
11.1	Introduction	377
11.2	Quantification of Local Proteolytic Activity – an Objective	380
11.2.1	Regulation of Protease Activity	382
11.2.1.1	Secretion	382
11.2.1.2	Activation	382
11.2.1.3	Inactivation	383
11.2.1.4	Endogenous Protease Inhibitors	383
11.2.1.5	Glycosylation	384
11.2.1.6	Oligomerization	384
11.2.1.7	Protein Trafficking	385
11.2.2	Mechanisms of Confining Proteolytic Activity	385
11.2.2.1	Membrane-type Matrix Metalloproteinases	386
11.2.2.2	Cell Surface Receptors for Protease Binding	387
11.2.2.3	ECM Binding of Proteases	387
11.2.2.4	Cellular Microdomains	388
11.2.2.5	The Tumor–Host Conspiracy	388
11.2.3	Local Proteolytic Activity Regulates Complex Cellular Functions	389
11.2.3.1	Local Proteolytic Activity in Cancer Cell Migration	389
11.2.3.2	Local Proteolytic Activity and Cell Signaling	389
11.2.3.3	Functional Insights from Matrix-metalloprotease Deficient Mice	390
11.3	Evaluation of Classical Methods for Quantification of Net Proteolytic Activity	391
11.3.1	Functional Detection of Local Proteolytic Activity by <i>In Situ</i> Zymography	392
11.3.2	Tumor Cell Invasion Assays	393
11.3.2.1	Electrical Resistance Breakdown Assay	394
11.3.3	<i>In vivo</i> Detection of Proteolytic Activity	394
11.3.4	Multiphoton Microscopy and Second-harmonic Generation	395
11.3.5	<i>In vitro</i> Detection of Local Proteolytic Activity by Labeled Substrates	396
11.4	Novel Approaches to Local Proteolytic Activity	396
11.5	Conclusions and Perspectives	400
	Acknowledgments	401
	Abbreviations	401
	References	401